Prospective Randomized Study Comparing Concomitant Chemoradiotherapy Using Three Weekly Cisplatin and Biweekly 5-Fluorouracil versus Weekly Paclitaxel in Locally Advanced Carcinoma Cervix

Sapna Marcus1  Jasmeet Kaur2  Hanuman Prasad Yadav3

1Department of Radiation Oncology, Crown Princess Mary Cancer Center, Sydney, Australia
2Department of Radiation Oncology, GGS Medical College and Hospital, Faridkot, Punjab, India
3Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India

Address for correspondence Sapna Marcus, MD, DNB, Department of Radiation Oncology, Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, NSW, Australia (e-mail: sapnamarcus@gmail.com).

Abstract

India being the second most populous country in the world accounted for 25% of cervical cancer death according to GLOBOCAN 2012. Although there are many agents available, the need for a model chemotherapy regimen that is effective and at the same time less toxic and has easy affordability is the current unmet need. We devised a study with the most commonly available and affordable drugs such as Cisplatin, 5-Fluorouracil (5FU), and Paclitaxel. The main objective was to study the efficacy of concurrent chemoradiotherapy in treatment of carcinoma cervix, using two different regimens in terms of clinical response evidenced clinically as well as on imaging. Secondary objectives were to assess the progression-free and overall survival. It was clearly evident that the response rate could be appreciated clinically in arm B over A; however, this difference could not be justified by statistical methods. Toxicities observed in both the arms was comparable, and in terms of progression-free and overall survival, the differences were not significant suggesting that the both the options could be considered in the treatment. Although the outcome looks promising prompting exploration of more such combinations that are easily available in the rural hospitals, but because of smaller sample size and smaller follow-up, a multi-institutional study with a larger sample size and a longer follow-up is definitely required to set the ball rolling in favor of combination chemotherapy, including cisplatin and 5FU.

Keywords

► 5-fluorouracil
► carcinoma cervix
► cisplatin
► overall survival
► progression-free survival

Introduction

In 2012, according to GLOBOCAN, there were 527,600 new cervical cancer cases and 265,700 deaths reported worldwide.1 Majority of global burden occurs in the less developed regions, where it amounts for 12% of all gynecologic cancers. Carcinoma cervix is the most common female malignancy in India with crude incidence rate of 23.5 per 100,000 women per year, and of the estimated 134,420 new cases every year, 72,825 women will die partially due to inadequacy of the current treatment.2–4

Radiotherapy is the mainstay of treatment for locally advanced cervical cancer. The ability of radiotherapy to cure locally advanced cervical cancer is limited by the tumor size because the doses required to treat large tumors exceeds the limit of radiation tolerance in normal tissue. Based on multicentric trials favoring chemoradiation compared with radiation alone for improved overall survival (OS) and reducing local and distant recurrence suggesting concomitant chemotherapy, the National Cancer Institute issued a clinical alert stating that “strong consideration should be given to the incorporation of concurrent
cisplatin-based chemotherapy with radiation in women who require radiation therapy in cervical cancer.\textsuperscript{5,6}

The reigning position of platinum agents in the treatment of advanced cervical cancer was questioned by the analysis of the Cochrane Collaboration meta-analysis in 2010, which showed that the benefit observed in previous concurrent chemoradiotherapy-based randomized trials may not depend on the use of platinum only.\textsuperscript{6} A randomized study by Christie et al confirmed that the addition of 5-Fluorouracil (5FU) to radiotherapy increased survival and local control.\textsuperscript{7} However, the role of 5FU, as a radio-sensitizing agent, is still severely underexploited; therefore, further research and trials are required on a broader scale for its role to be stated as a chemotherapeutic agent used in treatment of carcinoma cervix in a concurrent setting.

On the other hand, the role of taxanes has emerged recently in cervical cancer. Paclitaxel is a taxane-based alkaloid from pacific yew (\textit{Taxus brevifolia}) that inhibits tubular aggregation.\textsuperscript{8,9} Paclitaxel was found to have significant activity in solid tumors, especially epithelial ovarian, lung, and breast cancer.\textsuperscript{10} Preclinical studies have shown a radio-sensitizing effect of paclitaxel in human cervical cancer cell lines.\textsuperscript{11} Combination of cisplatin and paclitaxel has been used in metastatic or recurrent carcinoma of the cervix in various phases II and III trials with an objective response rate of 36 to 46%. It was affirmed by these trials\textsuperscript{11,14–16} that concomitant administration of cisplatin and paclitaxel was more effective than cisplatin alone in relapsed cases of advanced cervical cancer.

These facts have led many groups to investigate other drugs such as paclitaxel in an attempt to improve on what can be achieved by cisplatin alone. However, little evidence is there to prove that paclitaxel increases the overall response as compared with cisplatin.\textsuperscript{17,18} However, in a rural Indian setting where the standard treatment needs to be optimized with the primary drugs such as cisplatin, 5FU, and paclitaxel, it becomes imperative to devise an optimal regimen that can be used in a concomitant setting with radiotherapy to achieve maximum tumor control with minimum toxicity. This would not only improve compliance to the treatment owing to the less toxicity but also lead to improved OS and quality of life.

Materials and Methods

This was a 1-year randomized prospective study, including 60 histologically proven patients with carcinoma of the cervix in a tertiary cancer institute in a rural Indian setting. The main objective of this study was to assess the efficacy of two different regimens of concurrent chemoradiotherapy in a concurrent setting in treatment of carcinoma of the cervix in terms of compliance to treatment, toxicities, and progression-free survival (PFS).

Patients were randomized into two different arms using central computed randomization technique (\textit{Fig. 1}). The study arms were divided into arm A including patients receiving concurrent chemoradiotherapy with weekly paclitaxel (60 mg/m\textsuperscript{2}) and arm B who received concurrent chemoradiotherapy with 3 weekly cisplatin (50 mg/m\textsuperscript{2}) and biweekly 5FU (500 mg/m\textsuperscript{2}). There were 29 patients in arm A and 31 patients in arm B. Both the chemotherapy schedules were studied along with concurrent radiotherapy in terms of PFS, OS, and toxicities.

Inclusion Criteria

- Age < 70 years.
- European Cooperative Oncology Group (ECOG) performance scale of 1 or 2
- Biopsy-proven carcinoma of the cervix.
- Stage IIB–IVA carcinoma of the cervix. Staging will be done as per International Federation of Gynecology and Obstetrics (FIGO) staging 2009.
- Normal hematologic, renal, and hepatic functions profile.
- No prior chemotherapy or radiotherapy received.
- Signed written consent as per institutional regulation.

Exclusion Criteria

- Patients who have received chemotherapy or radiotherapy prior to this study will be excluded from the study.
- Patients not fulfilling the inclusion criteria are excluded from the study.

A dose of 5,000 cGy in 25 fractions over 5 weeks was given by external beam radiotherapy (EBRT) either by two or four fields, during which patients’ weekly assessment was done. After 1 week of completion of EBRT, patients were assessed for brachytherapy and those appropriate were taken up for the treatment. Patients were reassessed for clinical response using the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria. Radiation Therapy Oncology Group (RTOG) toxicity criteria were used to access radiation-induced toxicities. Patients were assessed by magnetic resonance imaging (MRI) at the end of treatment and thereafter at 6 weeks and at 6 months for disease response and were categorized in following groups accordingly:

- Complete responders: Complete regression of lesion.
- Partial responders: > 50% regression in lesion in maximum diameter.
- No responders: Lesion regressed < 50% in maximum diameter.

During statistical analysis of the findings, we used SPSS (Statistical Package for Social Sciences) version 17 (Chicago, IL, United States). We also analyzed the data using cross-tables and checked the significance using chi-square test for different variables. For assessing the PFS and OS, we used the Kaplan-Meier curves.

The strengths of this study were that it compared two schedules of chemotherapy, which have not been explored before in a head on trial setting along with concomitant radiotherapy. A different dosing schedule that was considered less toxic and more manageable as well as treatment compliant was adopted. The other favorable aspect of our study was that the drugs chosen for the study has already demonstrated efficacy as first-line drugs in treatment of carcinoma cervix and also had easy availability on a regular basis in a rural setting. The other most important strength

Asian Journal of Oncology Vol. 4 No. 2/2018
of this study was that the drugs used in the study were acceptable in terms of affordability, which has always been a limiting step in similar studies due to lack of any financial support from the institution or any medical companies. At the same time, the drawbacks of the study were the small size of the study, as well as its limited follow-up period due to its time-bound nature. Nevertheless, the results can always be reassessed after a longer follow-up for concrete analysis. We recommend that a long-term follow-up should be performed to remove confounding factors and provide authenticity to the study.

Results and Analysis

At the time of analysis of the results, two patients were lost to follow-up in arms A and B. In addition to this, in arm B, one patient was started on a different regimen due to intolerance to chemotherapeutic agent and one died during the treatment, leaving a total of 27 patients in each arm.

1. Patients in both the study groups were comparable regarding age distribution. The mean age ± SD (standard deviation) in arm A was 51.41 ± 9.544 years and in B was 48.85 ± 10.007 years. In our study, 60% of patients were in fourth and fifth decades.

2. Thirteen (48.1%) patients in arm A and 17 (63%) in arm B had ECOG PS of 1 at presentation, whereas 14 (51.9%) patients in arm A and 10 (37%) in arm B had ECOG PS of 2.

3. The most common histopathology was squamous cell variety found in 53 (98.15%) patients, followed by its variants in 1 (1.25%) patient. There were no cases of adenocarcinoma detected.

4. The distribution of patients according to stage at presentation is documented in Table 1.

Treatment Profile

All patients in the respective arms received radiotherapy with a combined dose of 80 to 85 Gy, delivered by EBRT and BRT. Patients in arm A received concurrent chemotherapy with weekly paclitaxel whereas those in arm B received concurrent chemotherapy with 3 weekly cisplatin and biweekly 5FU.

5. It was evident that 17 (63%) patients, less than two-third of the patients, completed five cycles (desired number) of weekly paclitaxel in arm A. However, in arm B, more than two-thirds of the patients, that is, 24 (88.9%) patients, completed more than two cycles (desired number) of cisplatin and approximately 18 (66.7%) patients completed more than seven to eight cycles of planned
5FU regimen. Overall treatment delay was observed in a total of 22 (40.74%) patients. This difference of treatment time delay in both the groups was not statistically significant (p = 0.857).

**Toxicity Profile**

6. Tables 2–4 show that incidence of treatment-related gastrointestinal (GI) toxicity. Most patients in both the groups did not show symptoms of toxicity during first week of treatment. Most toxicities occurred beyond second week and were grade 2 irrespective of the chemotherapy agents used. The difference between the toxicities was not statistically significant (p = 0.233).

7. While on the acute hematologic toxicity front, both the arms exhibited an uneventful first week, followed by grade 1 toxicity during the second week. From third week onward, as expected, the toxicity increased but more so in arm A than in B. During fourth week of treatment, almost all patients had grade 1 toxicity. The difference between the toxicity levels in both the arms was not statistically significant (p = 0.836). During fifth week of treatment, only two (7.4%) patients exhibited grade 3 toxicity, belonging to arm B.

8. In the case of chemotherapy-induced neutropenia, it was evident that most patients in both the arms had grade 1 toxicity, but the percentage of patients having grade 2 toxicity increased especially in arm A during the course of the treatment. During the entire treatment, none of the patient progressed to grade 3 or 4 toxicity. The difference was statistically nonsignificant (p = 0.217).

9. Representation of patients requiring hospital admission for the management of chemotherapy-related toxicities in both the arms is tabulated in Fig. 2.

**Tumor Response**

Tumor response was assessed clinically with MRI at completion of treatment, at 6 weeks, and subsequently at 6 months of treatment completion.

10. Tables 2–4 show that 19 (70.4%) patients in arm A and 23 (85.2%) in arm B had complete response at the completion of treatment (2A). The findings were consistent at 6 weeks and 6 months of treatment with 19 (70.4%) patients in arm A and 24 (88.9%) in arm B showing complete response (Tables 3, 4). Of patients showing partial response there were eight (29.6%) patients in arm A and three (11.1%) in arm B at treatment completion. The results were consistent at successive assessments. There is a difference of 18% in response rate in both the arms, which was appreciated clinically at 6 months; however, this difference is not statistically significant (p = 0.362) and therefore needs a larger sample size and a longer follow-up for validating our study.

**Table 1** Distribution of patients according to FIGO stage

<table>
<thead>
<tr>
<th>FIGO stage</th>
<th>Patients in arm A, n (%)</th>
<th>Patients in arm B, n (%)</th>
<th>Total number of patients, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2B</td>
<td>11 (40.7)</td>
<td>11 (40.7)</td>
<td>22 (40.7)</td>
</tr>
<tr>
<td>3A</td>
<td>3 (11.1)</td>
<td>1 (3.7)</td>
<td>4 (7.4)</td>
</tr>
<tr>
<td>3B</td>
<td>11 (40.7)</td>
<td>12 (44.4)</td>
<td>23 (42.6)</td>
</tr>
<tr>
<td>4A</td>
<td>2 (7.4)</td>
<td>3 (11.1)</td>
<td>5 (9.3)</td>
</tr>
<tr>
<td>Total</td>
<td>27 (100)</td>
<td>27 (100)</td>
<td>54 (100)</td>
</tr>
</tbody>
</table>


Distribution of patients according to the disease stage (Staging according to FIGO 2009.)

**Table 2** Distribution of patients according to tumor response at completion of treatment

<table>
<thead>
<tr>
<th>Response</th>
<th>Arm A, n (%)</th>
<th>Arm B, n (%)</th>
<th>Total number of patients, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>19 (70.4)</td>
<td>23 (85.2)</td>
<td>42 (77.8)</td>
</tr>
<tr>
<td>PR</td>
<td>8 (29.6)</td>
<td>3 (11.1)</td>
<td>11 (20.4)</td>
</tr>
<tr>
<td>PD</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SD</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Died</td>
<td>0</td>
<td>1 (3.7)</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Total</td>
<td>27 (100)</td>
<td>27 (100)</td>
<td>54 (100)</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Distribution of patients according to tumor response at 6 weeks of completion of treatment.

**Table 3** Distribution of patients according to tumor response at 6 weeks of completion of treatment

<table>
<thead>
<tr>
<th>Response at 6 wk</th>
<th>Arm A, n (%)</th>
<th>Arm B, n (%)</th>
<th>Total number of patients, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>19 (70.4)</td>
<td>24 (88.9)</td>
<td>43 (79.6)</td>
</tr>
<tr>
<td>PR</td>
<td>8 (29.6)</td>
<td>2 (7.4)</td>
<td>10 (18.5)</td>
</tr>
<tr>
<td>PD</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>SD</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Died</td>
<td>0</td>
<td>1 (3.7)</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>Total</td>
<td>27 (100)</td>
<td>27 (100)</td>
<td>27 (100)</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Distribution of patients according to tumor response at 6 weeks of treatment.

**Table 4** Distribution of patients according to tumor response at 6 months of completion of treatment

<table>
<thead>
<tr>
<th>Response at 6 mo</th>
<th>Arm A, n (%)</th>
<th>Arm B, n (%)</th>
<th>Total number of patients, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>19 (70.4)</td>
<td>24 (88.9)</td>
<td>43 (79.6)</td>
</tr>
<tr>
<td>PR</td>
<td>1 (3.7)</td>
<td>0</td>
<td>1 (1.9)</td>
</tr>
<tr>
<td>PD</td>
<td>5 (18.5)</td>
<td>2 (7.4)</td>
<td>7 (13)</td>
</tr>
<tr>
<td>SD</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Died</td>
<td>2 (7.4)</td>
<td>1 (3.7)</td>
<td>3 (5.5)</td>
</tr>
<tr>
<td>Total</td>
<td>27 (100)</td>
<td>27 (100)</td>
<td>54 (100)</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Distribution of patients according to tumor response at 6 months of completion of treatment.
11. Patients’ overall status was assessed from enrollment of the first patient till the last follow-up (►Table 5). Patients enrolled during initial period of study had longer follow-up than those enrolled in later period of study. Patients’ overall status observed at 6 to 8 months and beyond 8 months was almost equal in both the arms. It was clear that the incidence of residual disease was appreciably high in arm A, almost double to that of arm B. Also, the deceased patients in arm A were twice in number to that in arm B.

12. In terms of PFS and OS, there was no significant difference among the two arms ($p > 0.05$). The survival graph curve of arm B (►Fig. 3) is fairly better than that of arm A. However, as seen in our study, at some or the other point both curves interchange, so one group is better for some period of time, and at other point, the other group crosses it. In PFS, however, arm B is slightly better but not significantly. Also, we can see mean survival time graph that the arm B is better than A.

**Table 5** Distribution of patients according to PFS at 6 months of follow-up

<table>
<thead>
<tr>
<th>PFS (mo)</th>
<th>Arm A, n (%)</th>
<th>Arm B, n (%)</th>
<th>Total number of patients, n (%)</th>
<th>$p$-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 6</td>
<td>2 (7.4)</td>
<td>2 (7.4)</td>
<td>4 (7.4)</td>
<td>0.341</td>
</tr>
<tr>
<td>6–8</td>
<td>9 (33.3)</td>
<td>7 (26)</td>
<td>16 (29.6)</td>
<td></td>
</tr>
<tr>
<td>&gt; 8</td>
<td>16 (59.3)</td>
<td>18 (66.6)</td>
<td>34 (63)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>27 (100)</td>
<td>27 (100)</td>
<td>54 (100)</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>10.15 ± 3.708</td>
<td>11.15 ± 3.929</td>
<td>11 (100)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PFS, progression-free survival; SD, standard deviation. Distribution of patients according to PFS till 6 months of follow-up of the last patient enrolled in the study arms.

**Discussion**

To reach to an academic consensus on the standard chemotherapy schedule, amidst the wide range of options available is a gigantic task in itself. The optimal choice of chemotherapy is still a gray zone in terms of carcinoma of the cervix with its varied sensitivity to variable drugs. Therefore, this study was undertaken to throw new light on the possible combinations of the most common and easily available drugs in the rural settings of Northern India, which might prove to be more acceptable leading to increased compliance of the treatment.

The most common reasons for local recurrence have been attributed to incomplete treatments that in turn are caused mostly due to chemotherapy-induced toxicities and increased overall treatment time (OTT). Patients receiving chemoradiation have increased treatment-related toxicities as compared with those receiving radiation alone. Among them, the most common are nausea, enteritis, and hematologic toxicities. The most common reason for failure to complete chemotherapy as expected was GI toxicity. There was no correlation between failure to complete planned chemotherapy and patient age, disease stage, radiotherapy treatment volumes, or postoperative treatment. In a study...
by Jakubowicz et al, acute treatment-related toxicity grade 3 or 4 (World Health Organization [WHO]) occurred in 21.6% of patients including leucopoenia in 7.5%, anemia in 5%, nausea and vomiting in 3.3%, diarrhea in 5%, and urinary tract infection in 0.8%. In our study, a total of 97.3% of patients completed treatment without any interruptions for treatment-related toxicity. Only two (3.4%) patients experienced a delay in brachytherapy for treatment-related toxicity. The common toxicities observed in our study were GI and hematologic. However, this difference in the toxicities between the two chemoradiation groups was not statistically significant \((p = 0.440)\), irrespective of a combination chemotherapeutic schedule adopted in arm B. To emphasize, toxicities in both the arms were at an acceptable level, thereby offering an affordable. The other reason for increased recurrence rate is OTT. Median OTT of 8 weeks is considered optimal by various investigators. In our study, 17 (63%) patients in arm A, and 18 (66.7%) in arm B, which amounts to more than two-thirds of the target population, completed their prescribed treatment in the desired time frame of 8 to 9 weeks. The mean treatment duration in both the study arms was 60 to 68 days, which was longer than the standard accepted time period.

The reasons behind this was that ours was a tertiary care setup. With an ongoing academic program, many patients receiving treatment were from rural areas with compromised nutritional status and therefore required time for nutritional buildup or toxicity management. Also, most patients were from low socioeconomic status and uneducated, thereby undermining the importance of treatment.

In the study, clinical response assessed at completion of treatment confirmed that there was a difference of 18% in the response rate between two arms favoring arm B; however, this difference was not statistically significant \((p = 0.161)\). The clinical response attained at 6 weeks of treatment completion and at 6 months of follow-up was consistent. Stehman et al, in their study with concurrent chemoradiotherapy with cisplatin and 5FU, observed complete disappearance of all clinical evidence of disease in 65 (86.7%) of patients, with the complete response and partial response rate of 93.3%. The findings were affirmed with our study results with arm B containing 5FU and cisplatin regimen showing complete response rate of 88.9% and partial response rate of 95%. Whereas in defense for arm A, sufficient evidence was gathered by Umayahara et al, who in their study observed concurrent chemoradiation with weekly paclitaxel and cisplatin showing complete response in 85% patients. However, in our study, 70% complete response was seen in weekly paclitaxel arm. The reasons attributed for the slope in response rate could be because a single drug was used.

PFS and OS were also comparable in both the arms. The Kaplan-Meier graph curves demonstrated an early survival advantage with arm B initially, but in the latter part of the study, arm A took over and both the survival curves remained interchangeable during the study period. However, in our study, the main limitation was a relatively small sample size, which could be due to single institution study. Because of the study being conducted in a time-bound manner, enrolment was conducted for 1 year only. Further, because of the advanced-stage presentation and poor nutritional status, approximately 18% patients did not have adequate regression of the disease at the completion of EBRT and therefore could not be included for brachytherapy. The answers to this problem lie in conducting more multi-institutional trials to overcome the problem of small sample size. The incorporation of positron-emission tomography-based response-evaluation

![Fig. 3  Survival functions of both study arms.](image)
criteria (PERCIST) may improve accuracy of response assessment.

Therefore, the results in both the studies reaffirmed that concomitant chemoradiotherapy is the answer to locally advanced cervical carcinoma. There have been many chemotherapeutic agents that boast of high efficacy against the malignancy along with added radiosensitizing property, which are unfortunately not readily available or affordable at cancer centers in rural areas. However, there is still a persistent gray zone that needs reexploration at every angle, especially when it comes to a rural setup with limited resources.

The results observed were definitely in favor of the arm including cisplatin and 5FU showing clinically appreciable complete response rate and also decreased progressive disease. However, the results cannot be validated on concrete grounds, as of now due to study limitations. Therefore, based on these results, we can conclude that this study very efficiently opens new horizons in terms of newer schedules of the commonly available chemotherapeutic agents that can be exploited with different dosing and schedules to offer treatment benefits to patients with advanced cervical carcinoma where treatment-related toxicities and OTT delay pose a major problem in attaining complete response due to poor performance status of patients hailing from rural backgrounds.

**Funding**
None declared.

**Conflict of Interest**
None declared.

**References**